Receive our newsletter – data, insights and analysis delivered to you

Global clinical trials activity decreases 1% in Q1 2021 over 4Q average

The global clinical trials activity saw a decrease of 1% in Q1 2021, when compared with the rolling average of the last four quarters (Q1 2020 to Q4 2020), according to GlobalData.

Of the overall activity, industry sponsored trials accounted for a 51.5% share in Q1 2021, marking an increase of 3.6% in the total share when compared with the four-quarter average.

Non-industry sponsored trials accounted for a 48.5% share of all the clinical trials globally in Q1 2021, marking a decrease of 3.6% in the overall share when compared with the four-quarter average.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

 

Top therapy areas for industry and non-industry sponsored clinical trials in Q1 2021

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Oncology was the leading therapy area for industry sponsored clinical trials in Q1 2021, accounting for a 29.7% share of all trials.

This was followed by the following therapy areas: Infectious Disease with an 18.4% share, Central Nervous System with a 13.3% share, Metabolic Disorders with a 7.3% share and Cardiovascular with a 6.4% share.

In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 26.2% share, followed by Infectious Disease with a 21.2% share, Central Nervous System with a 12.6% share, Respiratory with a 9.3% share, and Metabolic Disorders with a 7.8% share.

Industry sponsored trials activity: 4-Quarter Avg. vs Q1 2021
Therapy Area 4-Quarter Avg. Q1 2021 Activity
Oncology 26.2% 29.7% Increase
Infectious Disease 21.2% 18.4% Decrease
Central Nervous System 12.6% 13.3% Increase
Metabolic Disorders 7.8% 7.3% Decrease
Cardiovascular 7.5% 6.4% Decrease
Respiratory 9.3% 5.8% Decrease
Gastrointestinal 6.4% 5.3% Decrease
Immunology 5.1% 5.1% Decrease
Musculoskeletal Disorders 3.5% 3.8% Increase
Dermatology 4.3% 3.3% Decrease
Ophthalmology 2.7% 3.3% Increase
Hematological Disorders 3.0% 3.1% Increase
Genito Urinary System And Sex Hormones 2.7% 2.2% Decrease
Genetic Disorders 1.5% 1.5% Decrease
Women’s Health 1.8% 1.4% Decrease
Ear Nose Throat Disorders 1.5% 1.0% Decrease
Male Health 0.9% 0.7% Decrease
Hormonal Disorders 0.5% 0.6% Increase
Mouth and Dental Disorders 0.5% 0.5% Decrease
Nutritional Disorders 0.4% 0.5% Increase
Non Malignant Disorders 0.2% 0.0% Decrease

 

Oncology was the leading therapy area for non-industry sponsored clinical trials in Q1 2021, accounting for a 27.8% share of all trials.

This was followed by the following therapy areas: Central Nervous System with a 24.8% share, Infectious Disease with a 16.8% share, Cardiovascular with a 9.3% share, and Musculoskeletal Disorders with a 5.0% share.

In the last four quarters, Infectious Disease System held a lead over others for non-industry sponsored clinical trials with an average share of 23.6%, followed by Oncology with a 22.2% share, Central Nervous System with a 20.4% share, Respiratory with an 8.9% share, and Cardiovascular with an 8.3% share.

Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q1 2021
Therapy Area 4-Quarter Avg. Q1 2021 Activity
Oncology 22.2% 27.8% Increase
Central Nervous System 20.4% 24.8% Increase
Infectious Disease 23.6% 16.8% Decrease
Cardiovascular 8.3% 9.3% Increase
Musculoskeletal Disorders 4.3% 5.0% Increase
Gastrointestinal 6.0% 4.7% Decrease
Respiratory 8.9% 4.6% Decrease
Metabolic Disorders 4.8% 4.5% Decrease
Immunology 2.8% 3.0% Increase
Women’s Health 4.4% 3.0% Decrease
Hematological Disorders 2.8% 2.9% Increase
Genito Urinary System And Sex Hormones 2.7% 2.5% Decrease
Dermatology 2.6% 1.8% Decrease
Mouth and Dental Disorders 1.9% 1.7% Decrease
Ophthalmology 1.4% 1.7% Increase
Ear Nose Throat Disorders 1.1% 0.9% Decrease
Hormonal Disorders 0.6% 0.7% Increase
Genetic Disorders 0.5% 0.6% Increase
Nutritional Disorders 0.7% 0.6% Decrease
Male Health 0.5% 0.5% Decrease
Non Malignant Disorders 0.4% 0.4% Decrease

 

Top regions in industry and non-industry sponsored clinical trials activity in Q1 2021

Asia-Pacific held the top position for industry sponsored clinical trials activity in Q1 2021 with a 46.7% share, compared to 53.8% in the last four quarters.

North America stood at second place with a 38.1% share in Q1 2021, over 31.6% in the last four quarters, followed by Europe with a 29.5% share in Q1 2021, as against 28.1% in the last four quarters.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held an 83.6% share in industry sponsored clinical trials in Q1 2021 when compared with 84.3% of average recorded in the last four quarters. Multinational trials accounted for a 16.4% share in Q1 2021, as against the four-quarter average of 15.7%.

Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q1 2021 with a 39.4% share, over 47.9% in the last four quarters.

North America held the second position with a 27.6% share in Q1 2021, over 17.3% in the last four quarters, followed by Europe with a 20.2% share in Q1 2021, as against 15.3% in the last four quarters.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held a 98.7% share for non-industry sponsored clinical trials in Q1 2021, compared to 98.8% in the last four quarters. Multinational trials accounted for a 1.3% share in Q1 2021, as against 1.2% in the last four quarters.

Industry and industry sponsored clinical trials by Phase in Q1 2021

Phase II trials outnumbered all other studies with a 39.7% share for industry sponsored trials in Q1 2021, compared to 34.6% average in the last four quarters.

The share of Phase I trials stood at 30.9% in Q1 2021, as against the four-quarter average of 36.4%. Phase III trials held an 18.0% share in Q1 2021, registering an increase of 0.9% over the last four quarters average, followed by Phase IV trials with an 11.4% share in Q1 2021, as against the four-quarter average of 11.9%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials outnumbered all other trials with a 49.5% share for non-industry sponsored clinical trials in Q1 2021, compared to 43.9% in the last four quarters.

Phase IV trials stood at second place with a 21.4% share in Q1 2021, compared to 19.4% in the last four quarters. Phase I trials held a 14.5% share in Q1 2021, as against 16.0% in the last four quarters, followed by Phase III trials with a 14.5% share in Q1 2021 over 20.8% average recorded in the last four quarters.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.
    Methodology:

    The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU